Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20008626 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)
Conditions: Thrombocytopenia;   MDS;   Myelodysplastic Syndromes;   Refractory Cytopenias
Intervention: Drug: Romiplostim

Indicates status has not been verified in more than two years